阿托伐他汀联合曲美他嗪对冠心病患者心功能和hs-CRP、IL-6、Fib的影响

目的 研究阿托伐他汀联合曲美他嗪对冠心病患者心功能和超敏C-反应蛋白（hs-CRP）、白介素-6（IL-6）、血浆纤维蛋白（Fib）的影响。方法 选择2014年1月-2016年1月在咸阳市第一人民医院进行诊治的冠心病患者120例，随机分为两组。观察组采用阿托伐他汀联合曲美他嗪治疗，对照组采用曲美他嗪治疗，观察和比较两组的疗效、左心室射血分数、左心室舒张末期内径、左心室后壁厚度及血清hs-CRP、IL-6、Fib水平。结果 观察组的治疗有效率为91.67%（55/60），明显高于对照组的76.67%（46/60）（P<0.05）；两组的左心室射血分数、左心室舒张末期内径、左心室后壁厚度均较治疗前明显改善（P<0.05），且观察组的改善程度明显优于对照组（P<0.05）；两组的血清hs-CRP、IL-6、Fib水平均明显降低（P<0.05），且观察组降低的更为明显（P<0.05）；两组不良反应发生率相比无明显差异。结论 阿托伐他汀联合曲美他嗪治疗冠心病患者疗效确切，能改善心功能，明显降低hs-CRP、IL-6、Fib水平，值得临床应用推广。

Effect of trimetazidine combined with atorvastatin on cardiac function andlevel of hs-CRP, IL-6, and Fib in patients with coronary heart disease

Objective To investigate the effect of trimetazidine combined with atorvastatin on cardiac function and the level of hs-CRP, IL-6, and Fib in patients with coronary heart disease. Methods Patients (120 cases) with coronary heart disease in the first people''s Hospital of Xianyang City from January 2014 to January 2016 were selected and randomly divided into two groups. The observation group was treated with trimetazidine combined with atorvastatin, the control group was treated with trimetazidine, the curative effect, left ventricular ejection fraction, left ventricular diastolic end systolic diameter, left ventricular posterior wall thickness and serum hs-CRP, IL-6, and Fib levels were compared. Results The effective rate of observation group was 91.67% (55/60), significantly higher than the control group 76.67% (46/60) (P<0.05); The left ventricular ejection fraction, left ventricular end-diastolic diameter, and left ventricular posterior wall thickness of two groups were significantly improved (P<0.05), and the improvement of the observation group was significantly better than that of control group (P<0.05); The serum levels of hs-CRP, IL-6, and Fib were significantly lower (P<0.05), and the observation group was more obvious (P<0.05); The incidence of adverse reactions of two groups had no significant difference. Conclusion Trimetazidine combined with atorvastatin have high curative effect on coronary heart disease, and can improve cardiac function, significantly reduce the levels of hs-CRP, IL-6, and Fib, worth clinical promotion.